Respiratory Failure Following Vinorelbine Tartrate Infusion in a Patient With Non-small Cell Lung Cancer

Vinorelbine tartrate (Navelbine [Burroughs Wellcome; Research Triangle Park, NC; Pierre Fabre Medicament; Paris, France]) is used in the treatment of non-small cell lung cancer (NSCLC), breast cancer, and some gynecologic malignant neoplasms. The reported prevalence of adverse effects involving the respiratory system is less than 5% and involves mostly dyspnea with occasional interstitial infiltrates. A patient with a hypercoagulable state and …